Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Meningioma microenvironment harbors a rich immune landscape with therapeutic implications (Bulk RNA-seq part)

ABSTRACT: Effective therapeutic targets are urgently needed for aggressive meningiomas. Given the pivotal role of immune microenvironment in tumor progression, we developed a comprehensive atlas of the meningioma microenvironment. Using single-cell and bulk techniques, we revealed a rich immune infiltrate in 2,610 meningiomas, among the highest observed across 34 human cancer types. Macrophages predominated in meningioma, contrasting with the lymphoid dominance of peripheral blood, with meninges exhibiting an intermediate immune profile. Cellular states and phenotypes of both immune and tumor cells shift during tumor progression toward an earlier-stage immune-suppressive and proliferative profile in aggressive meningiomas. Using ex vivo patient-derived tumor organoids, we demonstrated inducible responses to STING activation, marked by elevated cytokine release, which were synergistic when combined with PD-1 blockade. Together, these findings provide an extensive resource on the cellular heterogeneity of the meningioma microenvironment and provide a framework for rational therapeutic modeling and strategy development.

ORGANISM(S): Homo sapiens

PROVIDER: GSE290805 | GEO | 2026/02/11

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Meningioma microenvironment harbors a rich immune landscape with therapeutic implications (Single-cell RNA-seq part)

Project description:Effective therapeutic targets are urgently needed for aggressive meningiomas. Given the pivotal role of immune microenvironment in tumor progression, we developed a comprehensive atlas of the meningioma microenvironment. Using single-cell and bulk techniques, we revealed a rich immune infiltrate in 2,610 meningiomas, among the highest observed across 34 human cancer types. Macrophages predominated in meningioma, contrasting with the lymphoid dominance of peripheral blood, with meninges exhibiting an intermediate immune profile. Cellular states and phenotypes of both immune and tumor cells shift during tumor progression toward an earlier-stage immune-suppressive and proliferative profile in aggressive meningiomas. Using ex vivo patient-derived tumor organoids, we demonstrated inducible responses to STING activation, marked by elevated cytokine release, which were synergistic when combined with PD-1 blockade. Together, these findings provide an extensive resource on the cellular heterogeneity of the meningioma microenvironment and provide a framework for rational therapeutic modeling and strategy development.

2026-02-11 | GSE289349 | GEO

Integrative transcriptomics and network analysis reveals core genes driving meningioma pathogenesis and clinical outcomes

Project description:Meningiomas are the most common primary CNS tumors, often managed conservatively due to their benign histology. Molecular phenotyping is considered the current frontier in meningioma classification to predict progression and guide clinical management of adjuvant therapies. While several biomarkers have been studied, a definitive molecular prognostic panel has yet to be established—a gap this study seeks to address. Using patient-resected meningioma tumor tissues paired with normal meninges, transcriptomic analysis identified a subset of significantly differentially-expressed-genes(DEG) linked to cellular proliferation and immune suppression in the tumor microenvironment. Graph-theory analysis revealed a rich-club organization in the gene networks, with highly connected core nodes. Core gene expression levels significantly correlated with tumor WHO grading, achieving an ROC-AUC of 0.8 for distinguishing low-grade(grade-1) from high-grade(grades-2&3) tumors(P < 0.001). For clinical outcomes, core gene expression achieved an AUC of 0.96 for predicting tumor recurrence(P < 0.001) and 0.74 for patient survival(P = 0.018). This study employs an analytical pipeline integrating transcriptomic analysis of meningiomas with a graph-theory approach to identify core regulators within pathological tumor networks. This refined method facilitated the discovery of phenotype-encoding biomarkers, which accurately predicted histological grade and clinical outcomes. The identified core markers provide insights into meningioma-specific pathophysiological pathways and offer potential targets for therapeutic intervention.

2025-12-11 | GSE285889 | GEO

Human meningioma culture

Project description:Comparison of the gene expression profiles with meningiomas of different grading. 24 primary meningioma cultures from surgical specimen were maintained to primary meningioma cultures.

2014-03-06 | E-GEOD-55609 | biostudies-arrayexpress

Merlin S13 phosphorylation controls meningioma Wnt signaling and magnetic resonance imaging features

Project description:Meningiomas are the most common primary intracranial tumors and are associated with inactivation of the tumor suppressor NF2/Merlin, but one-third of meningiomas retain Merlin expression and typically have favorable clinical outcomes. Biochemical mechanisms underlying Merlin-intact meningioma growth are incompletely understood, and non-invasive biomarkers that predict meningioma outcomes and could be used to guide treatment de-escalation or imaging surveillance of Merlin-intact meningiomas are lacking. Here we integrate single-cell RNA sequencing, proximity-labeling proteomic mass spectrometry, mechanistic and functional approaches, and magnetic resonance imaging (MRI) across meningioma cells, xenografts, and human patients to define biochemical mechanisms and an imaging biomarker that distinguish Merlin-intact meningiomas with favorable clinical outcomes from meningiomas with unfavorable clinical outcomes. We find Merlin drives meningioma Wnt signaling and tumor growth through a feed-forward mechanism that requires Merlin dephosphorylation on serine 13 (S13) to attenuate inhibitory interactions with β-catenin and activate the Wnt pathway. Meningioma MRI analyses of xenografts and human patients show Merlin-intact meningiomas with S13 phosphorylation and favorable clinical outcomes are associated with high apparent diffusion coefficient (ADC) on diffusionweighted imaging. In sum, our results shed light on Merlin posttranslational modifications that regulate meningioma Wnt signaling and tumor growth in tumors without NF2/Merlin inactivation. To translate these findings to clinical practice, we establish a non-invasive imaging biomarker that could be used to guide treatment de-escalation or imaging surveillance for patients with favorable meningiomas.

2024-07-04 | PXD053578 | Pride

Proteomic analysis of meningioma of different grades identifies potential therapeutic targets and biomarkers

Project description:Meningiomas are common brain tumours arising from meningeal tissue. Despite the majority of them displaying benign features, they can cause mild to severe morbidity. The current main therapeutic approach is complete tumour resection commonly with adjunct radiation therapy. However, tumour location can hamper complete resection and chemotherapies are ineffective. In this study we aim to elucidate dysregulated pathways in meningioma pathogenesis and identify novel molecular targets by deciphering the proteome and phosphoproteome of different grades of meningiomas. Tumour lysates were collected from grade I, II and III frozenmeningioma specimens and three normal healthy human meninges.

2019-01-02 | PXD007125 | Pride

Proteomic analysis of meningioma of different grades identifies potential therapeutic targets and biomarkers

Project description:Meningiomas are common brain tumours arising from meningeal tissue. Despite the majority of them displaying benign features, they can cause mild to severe morbidity. The current main therapeutic approach is complete tumour resection commonly with adjunct radiation therapy. However, tumour location can hamper complete resection and chemotherapies are ineffective. In this study we aim to elucidate dysregulated pathways in meningioma pathogenesis and identify novel molecular targets by deciphering the proteome and phosphoproteome of different grades of meningiomas. Tumour lysates were collected from grade I, II and III frozemeningioma specimens and three normal healthy human meninges.

2019-01-07 | PXD007044 | Pride

Proteomic analysis of meningioma of different grades identifies potential therapeutic targets and biomarkers

2019-01-02 | PXD007073 | Pride

Affymetrix GeneChip miRNA 4.0 Array for meningioma recurrence profilling

Project description:Variability of meningioma growth, even within benign subgroup, makes some remain unaltered, while others grow fast despite an appended radiotherapy. Biomarkers that differentiate between less and more aggressive meningiomas would therefore have a significant clinical benefit in prediction of their biological behaviour. The aim of the study was to identify new candidate miRNAs enabling better and proper prediction of meningioma recurrence. We used miRNA 4.0 array (Applied Biosystems, Foster City, CA, USA) to detect miRNA profiles in 44 primary meningioma patients (19 with subsequent recurrence) and 5 healthy controls. Moreover, miRNA profiles were analyzed in 15 secondary meningiomas.

2019-02-15 | GSE126563 | GEO

Genomic profiling of anaplastic meningioma identifies recurrent genetic alterations with relevance to lower-grade meningioma

Project description:Genomic profiling of anaplastic meningioma can inform prognostic gene level alterations in lower-grade meningiomas, potentially reflecting evolution of anaplastic meningioma from lowergrade precursor tumours. Larger scale studies in paired primary and recurrent meningiomas are warranted to unravel the evolutionary path to anaplastic meningiomas and prognostic genomic alterations in detail

2021-05-04 | GSE173825 | GEO

MiRNA profiling of meningioma of different grades and histological subtypes

Project description:Although meningiomas are one of the most frequent primary intracranial tumors, there are only a few studies dealing with gene regulation processes in meningiomas. MiRNAs are key regulators of gene expression and regulation and miRNA profiles offer themselves as biomarkers for cancer development and progression. To investigate the role of miRNAs during meningioma growth and progression, we compared expression of 1205 miRNAs in 55 meningioma samples of different tumor grades and histological subtypes. We were able to classify histological subtypes in WHO grade I meningiomas with up to 97% accuracy (meningothelial versus fibroblastic) and different WHO grades with up to 93% accuracy (WHO I versus WHO III). We found significant downregulation of miRNAs on chromosome 1p36 and within two large miRNA clusters on 14q32 in high grade meningiomas, two regions that are yet associated with meningioma progression. We also identified several miRNAs associated with epithelial to mesenchymal transition differentially expressed in meningothelial meningioma compared to fibroblastic meningioma. Combined, our data show that meningiomas of different WHO grades and histological subtypes show a specific miRNA expression profile. Some individual miRNAs can also serve as potential biomarkers for meningioma progression.

2014-12-31 | GSE50641 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data